Table 4

The effects on steatosis of exposure to specific antiretroviral medication in 184 HIV-HCV coinfected patients according to the genotype
All patients (n=184)

Genotype 3

(n=47)

Other genotype

(n=132)

Antiretrovirals n

Adjusted OR

(95% CI)

p

Adjusted OR

(95% CI)

p

Adjusted OR

(95% CI)

p
NRTI 184 NE NE NE
zidovudine 144 1.11 (0.542.30) 0.77 0.91 (0.22-3.82) 0.90 1.42 (0.58-3.49) 0.45
lamivudine 161 1.10 (0.442.77) 0.82 0.50 (0.05-5.00) 0.56 1.29 (0.45-3.74) 0.64
stavudine 114 0.96 (0.511.78) 0.88 0.58 (0.14-0.47) 0.46 1.05 (0.51-2.17) 0.89
didanosine 105 1.20 (0.662.18) 0.57 1.02 (0.27-3.93) 0.97 1.17 (0.58-2.37) 0.66
zalcitabine 22 1.68 (0.604.72) 0.33 NE 1.29 (0.41-4.06) 0.66
tenofovir 24 0.87 (0.332.27) 0.78 0.15 (0.01-1.80) 0.13 1.44 (0.49-4.22) 0.51
abacavir 24 0.55 (0.221.39) 0.20 0.40 (0.07-2.40) 0.32 0.58 (0.18-1.84) 0.35
PI 126 1.15 (0.592.24) 0.67 0.19 -0.02-1.76) 0.15 1.46 (0.67-3.15) 0.34
ritonavir 55 0.90 (0.461.75) 0.75 0.54 (0.13-2.28) 0.40 1.04 (0.48-2.27) 0.91
indinavir 68 0.94 (0.511.74) 0.84 1.13 (0.29-4.41) 0.86 0.81 (0.39-1.68) 0.57
nelfinavir 47 0.96 (0.481.89) 0.91 0.37 (0.09-1.56) 0.18 1.19 (0.54-2.66) 0.66
saquinavir 31 0.91 (0.412.00) 0.81 0.41 (0.10-1.72) 0.22 0.94 (0.34-2.61) 0.91
lopinavir-ritonavir 17 0.55 (0.191.63) 0.28 0.45 (0.02-8.11) 0.59 0.67 (0.20-2.19) 0.50
atazanavir 8 0.76 (0.173.43) 0.72 NE 1.70 (0.31-9.24) 0.54
NNRTI 79 0.93 (0.501.74) 0.81 0.33 (0.08-1.27) 0.11 1.38 (0.65-2.95) 0.40
efavirenz 51 1.34 (0.672.69) 0.40 0.74 (0.17-3.27) 0.69 1.77 (0.79-4.00) 0.16
nevirapine 44 0.67 (0.331.35) 0.26 0.34 (0.08-1.38) 0.13 0.80 (0.35-1.83) 0.60

Adjusted for period of liver biopsy.

Abbreviations: OR, odds ratio; CI, confidence intervals; NE, not estimable.

Martinez et al.

Martinez et al. BMC Research Notes 2012 5:180   doi:10.1186/1756-0500-5-180

Open Data